#SFHS2614890AFrance adds Abbott ASSERT-IQ implantable cardiac monitors to reimbursable products list
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order adds Abbott Medical France’s ASSERT-IQ 3+ and ASSERT-IQ EL+ implantable ECG monitors to France’s reimbursable medical products list. The devices are covered for specific diagnostic uses, including recurrent unexplained fainting and certain unexplained ischemic strokes after standard neurological, vascular, cardiac, and biological checks have failed to identify a cause. Hospitals, cardiology teams, neurologists, and reimbursement teams should note the covered indications and prescribing conditions. Implantation must take place in a hospital setting under local anesthesia, and stroke-related use requires review by a multidisciplinary team including a neurovascular neurologist and a heart rhythm specialist.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds Abbott ASSERT-IQ 3+ and ASSERT-IQ EL+ implantable ECG monitors to France’s reimbursable products list
- Defines covered indications for recurrent unexplained syncope and certain unexplained ischemic strokes
- Sets clinical use conditions, including hospital implantation and multidisciplinary review for stroke-related cases
Obligations
What this law requires
Use ASSERT-IQ 3+ or ASSERT-IQ EL+ for reimbursed etiological diagnosis of recurrent unexplained syncope only after an initial clinical evaluation including history, physical examination with lying and standing blood pressure measurement, and 12-lead ECG.
For recurrent unexplained syncope patients without high-risk factors for sudden death, ensure there is no structural heart disease or coronary disease, no clinical or ECG abnormalities suggesting arrhythmic syncope, no major comorbidities such as severe anemia or electrolyte disorders, and a strong probability of recurrence during the device lifetime before claiming covered use.
For syncope patients at high risk of sudden death, use the implantable ECG monitor under the covered indication only when the complete initial workup, including electrophysiological investigation, has not enabled diagnosis or initiation of treatment.
For patients with probable or certain reflex syncope, reserve covered use for frequent and traumatic episodes where pacemaker implantation is being discussed if severe bradycardia is recorded.
Use ASSERT-IQ 3+ or ASSERT-IQ EL+ for reimbursed etiological diagnosis of ischemic stroke only in patients without contraindication to effective secondary preventive anticoagulation or left atrial appendage occlusion, and only when no cardioembolic source or coagulation disorder has been identified.